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Degree of Change in Mitral Regurgitation (MR) Following TAVI
DEGREE OF
MR
No. of Pt
Pre (%)
No. of Pt
Post (%)
P.
VAL.
No MR 3 (6%) 16 (32%) 0.001
Mild MR 20 (40%) 22 (44%) NS
Moderate MR 21 (42%) 10 (20%) 0.001
Severe MR 6 (12%) 2 (4%) NS
TF - TRANSFEMORAL
TA - TRANSAPICAL
NS - not significant
S - Significant
Conclusion: Degree of MR Improvement achieved in 56% patient. The predictor factor
that influence the reduction of severity of MR Post TAVI are a) Hypertension b) change
in the degree of Pulmonary Artery Pressure post TAVI.
However the eteology of MR, change in aortic gradient and change of LV function
post TAVI were not significant predictor.
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Factors Predicting Prolonged Hospital Stay After TAVI
Margarita Sirotina, Johannes Weber, Malte Buergstein, Ilona Hofmann, Horst Sievert
CardioVascular Center, Frankfurt am Main, Germany
Background: Transcatheter aortic valve implantation (TAVI) has become a valuable
alternative to aortic valve replacement (AVR) for surgical high-risk patients with severe
aortic stenosis. Due to technical improvements and increased operator experience the valve
implantation success has become very high. Nevertheless, the post procedural recovery in
these elderly patients is often prolonged. We aimed to evaluate clinical and demographic
predictors of a prolonged hospital stay in patients undergoing TAVI.
Methods: We included 187 consecutive patients with severe aortic stenosis who
underwent TAVI. The valve was implanted by transfemoral technic in 180 (96.3%),
transapical in 2 (1.1%) and via the subclavian artery in 5 (2.7%) patients. We implanted
160 (85.6%) CoreValve and 27 (14.4%) Edwards Sapien prostheses. Logistic regression
was used to determine the factors affecting length of stay longer than median.
Results: Median of length of stay was 7 days. Pulmonary hypertension above 60mmHg,
prior ischemic stroke, EuroSCORE II above median (5.3%) and previous cardiac surgery
did not have significant influence on the length of hospital stay (LOS). The following
parameters could be identified as predictors of a hospital stay  7 days (table 1).
Conclusion: Age above 85, STS-Score above median (5.6%), female gender, state of
chronic renal failure 3, logistic EuroSCORE above median (14.7%) are associated with
an increased risk of a longer hospital stay after TAVI. Independent predicting risk factors
are only the STS Score above median (5.6%) and the age above 85.
Table 1. Predictors of LOS > 7 days
Odds
ratio
95%
CI p-value
State of chronic renal failure  3 1.9 1.1-3.5 0.03
STS-Score1  median (5.6%) 2.5 1.4-4.5 0.003
EuroSCORE Log2  median (14.7%) 1.9 1.1-3.4 0.03
Age  85 2.6 1.3-5.5 0.01
Female Gender 2.0 1.1-3.6 0.03
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A Propensity Analysis
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Objectives: The aim of this study was to compare surgical outcome of patients with
previous cardiac surgery undergoing transapical aortic valve implantation (Redo-TAVI) to
those undergoing classic aortic valve replacement (Redo-AVR) by using propensity
analysis.
Background: TAVI has been suggested as an alternative to surgery in elderly patients
considered inoperable or high risk for surgical aortic valve replacement.
Methods: From January 2005 through Mai 2012, 52 high risk patients underwent
Redo-TAVI using a pericardial xenograft fixed within a stainless steel, balloon-
expandable stent (Edwards SAPIENTM). During the same period of time 167 patients
underwent classic Redo-SAVR. Logistic regression analysis was used to identify covariates
among 10 baseline patient variables including the type of initial surgery. Using the
significant regression coefficients, each patient’s propensity score was calculated, allowing
selectively matched subgroups of 40 patients each. Initial surgery included CABG in 29
patients and valve surgery in 11 patients in each group. Operative outcomes were analyzed
for differences. Follow-up was 42 years and 100% complete.
Results: Postoperative chest tube drainage (163214 vs 562332 ml/24h, p: 0.024),
incidence of permanent postoperative neurologic events (0 vs 13%, p: 0.012) and 30 day
mortality (10 vs 20%, p: 0.046) was lower in patients with Redo-TAVI as compared to
Redo-AVR. There was a trend towards a decreased ventilation time and need of
transfusion of packed red blood cell concentrates in the Redo-TAVI group (p: 0.078).
One patient in the Redo-TAVI group required temporary cardiopulmonary bypass
support. During late follow up there was no significant difference regarding mortality (10
vs 13%) and incidence of stroke (0 vs 3%, p:0.11).
Conclusions: Despite the limited number of patients, current data suggest a faster
postoperative recovery and reduced perioperative morbidity and mortality with Redo-
TAVI as compared to classic Redo-AVR. This evolving approach has reduced surgical
trauma and may be particularly applicable to elderly high risk patients with previous
cardiac surgery.
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Long-Term Results Following Transcatheter Aortic Valve Replacement (TAVR)
Pablo Codner, Abid Asali, Hanna Vaknin-Assa, Yaron Shapira, Gabriel Greenberg,
Katia Orbin, Marina Kupershmidt, Tamir Bental, Alexander Battler, Alexander Sagie,
Ran Kornowski
Rabin Medical Center, Petah Tikwa, Israel
Background and Aim: TAVR is an emerging technique for the treatment of severe
symptomatic aortic stenosis (AS). Few data reported the long-term outcomes of patients
undergoing TAVR. Thus, we aimed to focus on the prolonged results of the TAVR
procedure.
Methods: We analyzed the outcomes of 190 TAVR treated patients that were followed
up to 3 years. All patients were at very high risk for surgical valve replacement. The
Medtronic-CoreValve device was utilized in 64.2% and the Edwards-SAPIEN device in
35.7% of patients. The primary end point was death from any cause during follow up.
Results: The mean (SD) patient age was 82.15.7 years (60.5% female). Procedural
success rate (per VARC) was 96.8%. At 30 days, all-cause mortality was 3.1% and stroke
rates 3.7%. Two years follow up was obtained in 112 patients. All-cause mortality was
recorded in 13.6% of treated patients (4.2% cardiac mortality). No significant differences
in mortality were found when angioplasty was performed prior or during TAVR
compared to TAVR alone. Multivariate analysis showed that increased baseline creatinine
(HR 1.47; 95% CI 0.92-2.34; p0.099) and increased LogEuroSCORE (HR 1.03; 95%
CI 1.01-1.07; p0.017) predicted all-cause mortality.
Conclusion: According to our clinical experiences, the long-term prognosis of ‘all
comers’ TAVR patients is favorable.
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Clinical Outcome In Patients With Low Left Ventricular Function Undergoing
Transcatheter Aortic Valve Replacement
Israel Barbash, Danny Dvir, Saar Minha, Itsik Ben Dor, Salem Badr, Joshua P Loh,
Lakshmana Pendyala, Hironori Kitabata, Rebecca Torguson, Petros Okubagzi,
William Suddath, Lowell Satler, Kenneth Kent, Augusto Pichard, Ron Waksman
MedStar Washington Hospital Center, Washington, DC
Background: Left ventricular ejection function (LVEF) recovers in the majority of
patients with aortic stenosis (AS) who undergo aortic valve replacement. However the
outcomes of patients with low EF who undergo transcatheter aortic valve replacement
(TAVR) are not well defined.
Methods: Retrospective analysis of AS patients with normal versus mildly or severely
impaired left ventricular function who underwent TAVR was done. Patients were divided
according to baseline LVEF as normal (LVEF  0.50), mild-moderate (0.40  EF 
0.50) and severe (LVEF0.40) dysfunction.
Results: A total of 242 patients were included in the present analysis. 163 patients (67%)
had normal LVEF, 43 had mild-moderate (18%) and 36 (15%) had severe LV
dysfunction. Baseline demographics were generally comparable apart from higher rates of
women and STS score among patients with LV dysfunction (Table). There was no
difference in access approach with 72% of the patient having transfemoral access. No
significant difference in the in hospital and long term outcome were found (Table).
Conclusions: Patients with severe AS and impaired LV function who undergo TAVR
may gain similar benefit from the procedure as patients with normal LV function.
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Initial US Experience with Commercial Transfemoral Sapien Transcatheter Heart
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Salem Badr, Danny Dvir, Rebecca Torguson, Satler Lowell, Augusto Pichard,
Ron Waksman
MedStar Washington Hospital Center, Washington, DC
Background: Edwards Sapien transcatheter valve is FDA approved for commercial use
in non-operable patients with severe symptomatic aortic stenosis (AS) via the transfemoral
approach.
Objective: To assess the clinical profile and in-hospital complications in patients treated
with commercial valve compared to PARTNER cohort B.
Methods: Study included all consecutive patients treated with commercial Sapien valve
at our institution. Baseline characteristics, clinical presentation and in-hospital complica-
tions were analyzed. Among all trasfemoral cases 37 commercial valve patients were
compared to 54 patients in cohort B.
Results: All clinical variables are similar between the groups including STS score (9.44
vs. 10.75, p0.24) except commercial patients had more insulin dependent diabetes
mellitus and dialysis dependent renal failure. In majority of the patients in the commercial
arm the procedure was done with conscious sedation (81% vs. 56%, p0.02). The use of
planned surgical cut down for vascular access is also rare (4% vs. 85%, P0.001) in
commercial group. 100% procedural success in both the groups with valve deployment.
There is trend for lower vascular and bleeding complications with less blood transfusion
rates (27% vs. 59%, p0.007) in the commercial patients. The in-hospital mortality and
stroke rates are similar between the groups.
Conclusions: The initial commercial use of the Edwards Sapien valve for inoperable
patients reported to have similar success rates in valve deployment, in-hospital mortality
and stroke rate when compared to PARTNER cohort B patients. The refinement in the
procedure with more conscious sedation, experience of the operators and careful vascular
planning with more percutaneous access in the commercial group lead to the trends for
lower vascular complications and the requirement of blood transfusions.
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